9 recruiting, 5 active not recruiting, 3 completed, 2 terminated. 10 Phase 1, 6 Phase 2, 4 Early Phase 1, 2 Not applicable, 1 Phase 3.
Follow Advanced Ovarian Carcinoma: new trials by email Literature Review of Advanced Ovarian Carcinoma trials Research Report on Advanced Ovarian Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy Biospecimen Collection, Placebo Administration, Probiotic - Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma | Early Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 161 | 2026-03-06 | 2026-08-17 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors REVITALIZE Intervention, Educational Materials - Ovarian Cancer, Advanced Ovarian Carcinoma | Not applicable | Recruiting | Dana-Farber Cancer Institute | 240 | 2025-03-17 | 2026-04-13 |
| Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial Biopsy, Biospecimen Collection, Computed Tomography - Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 78 | 2024-11-12 | 2026-10-02 |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NKT3964, Paclitaxel, Doxorubicin - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 238 | 2024-09-19 | 2026-10-16 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment - Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 220 | 2023-08-23 | 2026-04-20 |
| ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer Wee1 Inhibitor ZN-c3 - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-07-30 | 2023-05-06 | |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours OATD-02 - Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | Molecure S.A. | 40 | 2023-01-26 | 2026-07-31 |
| Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression Claudin 18.2 CAR-T - Gastric Cancer, Pancreatic Cancer | Phase 1 | Unknown | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2022-08-08 | 2024-03-06 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Behavioral Counseling, Nutritional Supplement Drink, Physical Activity - Advanced Ovarian Carcinoma, Stage IIIC Fallopian Tube Cancer AJCC v8 | Not applicable | Completed | Mayo Clinic | 90 | 2021-10-05 | 2025-08-08 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Cisplatin, Elimusertib, Gemcitabine Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2021-08-25 | 2026-07-31 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial Chemotherapy, Laparotomy, Minimally Invasive Surgery - Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Recruiting | M.D. Anderson Cancer Center | 580 | 2020-08-05 | 2026-09-14 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 15 | 2017-07-14 | 2026-07-08 |
| Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Adavosertib, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2016-02-04 | 2026-10-06 |
Showing 20 of 22. Sign in to see all of them.
Ovarian Neoplasms (17) · Fallopian Tube Neoplasms (8) · Pancreatic Neoplasms (6) · Triple Negative Breast Neoplasms (5) · Carcinoma, Renal Cell (3) · Endometrial Neoplasms (3) · Lung Neoplasms (3) · Neoplasm Metastasis (3) · Prostatic Neoplasms (3) · Small Cell Lung Carcinoma (3) · Stomach Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Transitional Cell (2) · Colorectal Neoplasms (2)
Neoplasms (20) · Neoplasms by Site (19) · Adnexal Diseases (18) · Endocrine Gland Neoplasms (18) · Endocrine System Diseases (18) · Female Urogenital Diseases (18) · Female Urogenital Diseases and Pregnancy Complications (18) · Genital Diseases (18) · Genital Diseases, Female (18) · Genital Neoplasms, Female (18) · Urogenital Diseases (18) · Urogenital Neoplasms (18) · Gonadal Disorders (17) · Ovarian Diseases (17) · Digestive System Diseases (10)
Specimen Handling (7) · Biopsy (4) · Gemcitabine (4) · Magnetic Resonance Spectroscopy (3) · Paclitaxel (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · BAY 1895344 (2) · Bevacizumab (2) · Cisplatin (2) · Letrozole (2) · Leukapheresis (2) · Taxes (2) · atezolizumab (2) · cabozantinib (2)
M.D. Anderson Cancer Center (3) · Mayo Clinic (3) · National Cancer Institute (NCI) (3) · OHSU Knight Cancer Institute (3) · NiKang Therapeutics, Inc. (2) · Cascadian Therapeutics Inc. (1) · Dana-Farber Cancer Institute (1) · Molecure S.A. (1) · Northwestern University (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · Suzhou Immunofoco Biotechnology Co., Ltd (1) · University of Oklahoma (1)
United States (18) · Canada (2) · China (1) · Italy (1) · Mexico (1) · Netherlands (1) · Poland (1) · South Korea (1)
Alexi A Wright, MD, MPH (1) · Amanika A. Kumar, MD (1) · Apostolia M Tsimberidou (1) · Charles D Lopez, MD, PhD (1) · D. Scott McMeekin, MD (1) · Devalingam Mahalingam (1) · Evthokia Hobbs, M.D. (1) · Haiying Cheng (1) · James M Cleary (1) · Joanna J Arch, PhD (1) · Jose A Rauh-Hain (1) · Lara Davis (1) · Laura Chambers, DO (1) · Luo Tianhang, MD (1) · Mamta Parikh (1)
PMID 32379297, PMID 39570589, PMID 41928160, PMID 42847673
P30CA016056 (1), P30CA060553 (1), R01CA164333 (1), R01CA289547 (1), UM1CA186709 (1), UM1CA186717 (1)